Phosphatidylinositol 3-kinase (PI3K) pathway activation has been suggested to negatively influence response to anti-HER2 therapy in breast cancer patients. The present study focused on mutations of theThese results confirm that the outcome of HER2-positive patients treated with trastuzumab is significantly worse in patients with